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First Case of TARDBP-Related Amyotrophic 
Lateral Sclerosis in Korea
Dear Editor 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by 
the progressive degeneration of motor neurons. The cause of most cases of ALS is unknown, 
but 5–10% of them can be attributed to genetic alterations.1 Currently, 71 causative genes 
have been identified as causing familial ALS (www.musclegenetable.fr). Among them, 
C9ORF72 and SOD1 are the most common causative genes in European and Asian popula-
tions, respectively. Additionally, alterations in TARDBP and FUS each account for approxi-
mately 5% of patients with familial ALS.1,2 However, a pathogenic variant of TARDBP has 
not been reported in Korea.3,4 Herein we report a pathogenic variant of TARDBP in a Korean 
patient with familial ALS.
A 52-year-old male (II-11) (Fig. 1A) was referred to our institute with progressive muscle 
weakness. He had a family history of ALS in his mother (I-2) and elder sister (II-4), who 
had progressive asymmetric muscle weakness and died from respiratory failure in their 60s 
and 50s, respectively. The muscle weakness and wasting in the index patient had started in 
his right leg at the age of 50 years and progressed to his left leg and arm. A physical exami-
nation showed muscle weakness, wasting, and fasciculations in both legs and the left arm. 
The deep tendon reflexes in the bilateral knees and left arm were hyperactive. However, 
cognitive dysfunction, sensory deficits, and ataxia were not found. Magnetic resonance im-
aging showed only mild parenchymal atrophy in the brain and spinal cord. An electrophysi-
ological examination revealed a widespread neurogenic process without sensory nerve in-
volvement in the cervical, thoracic, and lumbosacral segments. The patient was diagnosed 
with clinically probable ALS, after which we performed targeted sequencing of 172 neurop-
athy-related genes (Supplementary Table 1 in the online-only Data Supplement) and iden-
tified a heterozygous pathogenic variant of TARDBP (NM_007375.4: c.1009A>G; 
NP_031401.1:p.M337V) (Fig. 1B). This variant was previously reported as a pathogenic vari-
ant in ALS.2
We speculate that the c.1009A>G variant should be classified as a likely pathogenic variant 
based on the following evidence: 1) located in a mutational hotspot without benign variation, 
2) not in Genome Aggregation Database (gnomAD), 3) low rate of benign missense varia-
tion in TARDBP, 4) multiple lines of computational evidence supporting a deleterious effect
on the gene, 5) a well-established in-vivo functional study having supported a damaging ef-
fect on the gene, and 6) many previous reports of it being a pathogenic variant.2,5,6
The TDP-43 protein encoded by TARDBP is a widely expressed RNA/DNA-binding pro-
tein involved in the regulation of RNA processing and other cellular functions.7 Most patho-
genic variants of TARDBP (including c.1009A>G) are located in the C-terminal glycine-rich 
domain. An abnormal C-terminal domain is believed to improve the aggregation propensity 
of the TDP-43 protein, which results in neurodegeneration. However, it is unclear whether 
the pathogenesis is linked to aggregates of the TDP-43 protein or impairment of the normal 
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function of this protein.7 
We have herein reported the first case of pathogenic variant 
of TARDBP in a Korean patient with familial ALS. Our patient 
showed adult-onset asymmetric muscle weakness without 
cognitive impairment. His muscle weakness began at the age 
of 50 years, which is similar to the onset ages in previous re-
ports. However, TARDBP-related ALS is well known to have a 
highly variable clinical presentation, including in the distribu-
tion of muscle weakness, severity of the disease, and presence 
of cognitive impairment.6 These characteristics make TAR-
DBP-related ALS indistinguishable from sporadic or other ge-
netic ALS based on clinical and electrophysiological features. It 
is essential to perform genetic testing on as many ALS-related 
genes as possible when diagnosing familial ALS.
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Fig. 1. Pedigree and sequencing chromatogram. A: Pedigree of a patient with familial amyotrophic lateral sclerosis. Arrow indicates the proband 
(square, male; circle, female; filled, affected; unfilled, unaffected). B: Sequencing chromatograms of the c.1009A>G variant of TARDBP. Arrow indi-
cates the site of the pathogenic variant.
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